'Vyloy' to expand treatment options for gastric cancer
By Whang, byung-woo | translator Hong, Ji Yeon
24.12.19 05:59:44
가나다라
0
Cumulative subgroup analysis from the POTLIGHT‧GLOW study reconfirms its effects on Korean patients
Concerns about companion diagnostics, which is used to diagnose Claudin-18.2, have been resolved. Companion diagnostics are being assessed as a new health technology
Has applied for reimbursement in October with plans to launch as non-reimbursed drug in January…"anticipating its many uses"
Vyloy (active ingredient: zolbetuximab), a Claudin-18.2-targeting gastric cancer therapy, is rising as the new treatment option for stage 4 gastric cancer despite an issue related to companion diagnostics.
As the number of newly diagnosed patients with Claudin-18.2 increases in clinical practices, the drug will be more widely used from the early next year when it launches as non-reimbursed.
▲Vyloy logo
Vyloy is the first and only Claudin-18.2-targeted treatment. A monoclonal antibody that is designed to work by binding to It binds to Claudin-18.2, a protein expressed in the stomach.In South Korea, Vyloy was approved by the Ministry of Food and Drug Safety (MFDS) as a 'First-line trea
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)